Rosacea Pipeline Watch: Journey Medical Submits NDA for DFD-29
Journey Medical Corporation has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the treatment of inflammatory lesions and erythema of rosacea in adults. DFD-29 is being developed in collaboration with Dr. Reddy’s Laboratories Ltd. “Based on the […]